Nocturnal Immuno Vestibular Oral Therapy administers allergens to the oral vestibular space at night, reducing symptom scores and adverse reactions.
Cross-flow microfiltration concentrates allergenic extracts without pH adjustment, preserving natural protein structures for stable therapeutic use.
Virus-like particles carrying truncated Fel d1 proteins induce specific antibodies in cats, resolving trade-offs between efficacy and allergic side effects.
Glutaraldehyde polymerization creates allergoids that eliminate dose escalation protocols while maintaining immunogenicity.
Charged self-assembling peptides create a hydrogel adjuvant that enhances immunogenicity by maintaining antigen presentation via electrostatic forces.
Thermosensitive gelatin enables controlled dissolution of cedar pollen allergens, avoiding refrigeration and heat degradation during production.
Recombinant Art a 1 production via Pichia pastoris resolves natural extract variability, ensuring consistent allergen purity for reliable diagnosis.
Gradual dose escalation of peanut protein reduces allergic reactions while extending treatment duration beyond two years.